Nerve block or lidocaine drip: which eases breast cancer surgery pain better?
NCT ID NCT07108959
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compared two ways to manage pain during breast cancer surgery: a nerve block (erector spinae plane block) and a lidocaine drip given through a vein. Researchers measured inflammation markers and pain levels in 40 women undergoing surgery. The goal was to see which method better reduces inflammation and improves recovery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lidocaine infusion and erector spinae plane block (nerve block procedure)
- What this could lead to
- If successful, this could point toward a better way to manage pain and inflammation during breast cancer surgery, potentially improving recovery.
- What could go wrong
- This is a small, completed study with only 40 participants, so results may not apply to all patients. The findings are preliminary and need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 30 -60 years. * Female patients. * ASA physical status class I - II. * Elective resectable non metastatic breast cancer. Exclusion Criteria: * Patients with history of sensitivity to the studied drugs. * Patients with cardiac conduction defects. * Patients with major spine deformities. * Patients with severe coagulopathy. * Patients with infection at injection site. * Patients with preexisting myopathy or neuropathy because it can worsen neurological deficits and increase sensitivity to local anaesthetic toxicity. Additionally, it complicates diagnosis of new symptoms and carries higher medicolegal risk due to difficulty distinguishing anaesthesia effects from disease progression. * Psychiatric disease or seizure disorder requiring medication within the previous 2 years. * Opioid tolerant patient. * Cognitive dysfunction. * Body Mass Index ( BMI ) more than 35 kg/m2 or less than 18 kg/m2 .
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine , Alexandria University
Alexandria, Alexandria Governorate, 21526, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?